# Study to Evaluate the Efficacy and Safety of KBP-042 in Patients With Type 2 Diabetes

> **NCT03230786** · PHASE2 · COMPLETED · sponsor: **KeyBioscience AG** · enrollment: 255 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Daily injection of KBP/placebo for 12 weeks as add-on to metformin

## Key facts

- **NCT ID:** NCT03230786
- **Lead sponsor:** KeyBioscience AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-23
- **Primary completion:** 2018-07-09
- **Final completion:** 2018-07-31
- **Target enrollment:** 255 (ACTUAL)
- **Last updated:** 2018-09-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03230786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03230786, "Study to Evaluate the Efficacy and Safety of KBP-042 in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT03230786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*